Date: 2015-03-02
Type of information: Publication of results in a medical journal
phase: 1
Announcement: publication of results in The Lancet Infectious Diseases
Company: Themis Bioscience (Austria)
Product: vaccine against Chikungunya fever
Action
mechanism: vaccine. This vaccine is based on the company´s own Themaxyn platform. This platform has been licensed by the Pasteur Institute in Paris and forms the basis for all vaccine candidates of the Vienna-based company.
The Themaxyn platform allows for the introduction of exceptionally long gene sequences of pathogens into the patient´s immune system. This allows for the possibility of mobilizing immune responses against several pathogen cell structures with a single vaccine. This possibility is particularly interesting with regard to a second vaccine currently being developed by Themis - a Dengue fever vaccine. In the case of Dengue fever, four serotypes of the pathogen are actually known and immunization against one of them does not protect against infection by another serotype.
Disease: Chikungunya fever
Therapeutic area: Infectious diseases
Country: Austria
Trial
details: The vaccine candidate, which is based on a standard anti-measles vaccine, will be evaluated on 36 candidates in the Department of Clinical Pharmacology at Vienna General Hospital. The primary goals of this recently launched study are to demonstrate the safety of the vaccine, as well as its ability to generate a strong immune response. At the same time, the study will provide the clinical \"proof of concept\" for Themis´ vector technology.
Latest
news: The candidate vaccine raised concentrations of neutralising antibodies to chikungunya in all dose cohorts after one immunisation, with seroconversion* rates of participants producing anti-chikungunya antibodies of 44% in the low, 92% in the medium, and 90% in the high-dose group. The immunogenicity of the candidate vaccine was not affected by pre-existing anti-measles immunity. The second vaccination resulted in a 100% seroconversion for all participants in the candidate vaccine groups. The candidate vaccine had an overall good safety profile, and while the rate of adverse events increased with vaccine dose and volume, no vaccination-related serious adverse events were recorded. The company now aims to move rapidly into phase II studies. * On November 20, 2014, Themis Bioscience announced that the induction of neutralizing antibodies by a prophylactic Chikungunya vaccine candidate has now been confirmed by the final results of a phase 1 clinical trial, as well as its tolerability and safety. The study was carried out on 42 subjects at the Department of Clinical Pharmacology of the Vienna General Hospital (Allgemeines Krankenhaus der Stadt Wien) and confirms the previous interim results: The candidate not only proved to be well tolerated and safe, but also exhibited the required immune response in the form of neutralizing antibodies in all vaccinated subjects. The immune response was clearly dose-dependent with even the lowest dose being effective. Details on the clinical trial were recently presented at two international conferences, namely the 26–28 October "8th Vaccine & ISV Congress" in Philadelphia, USA and the 2–6 November "ASTMH 63rd Annual Meeting" in New Orleans, USA. Commenting on the success of this Chikungunya phase I study, Themis' founder and CEO, Dr. Erich Tauber, states: "We could confirm that our Chikungunya vaccine candidate is well tolerated, safe and elicits the expected immune response. Considering the ongoing spread of Chikungunya epidemic, we now focus on making the vaccine available as soon as possible. We will also strengthen our already successful alliance with the Institut Pasteur." Themis and the Institut Pasteur will extend their collaboration towards a common goal of developing vaccines against numerous infectious diseases based on that vector. The pipeline already includes a dengue fever vaccine candidate, and the two partners will now collaborate on using Themaxyn® for additional targets. Frédéric Tangy, Institut Pasteur, states: "The phase I results of the Chikungunya vaccine candidate prove that the measles vector vaccine platform can be used successfully to develop a new generation of prophylactic vaccines, and the Institut Pasteur, which developed its core technology, is keen to strengthen its alliance with Themis to develop those innovative vaccine candidates."
In addition to this, the Themis team is already developing vaccine candidates of the second generation against Dengue fever - and securing options for itself for the development of vaccines against yellow fever, Japanese encephalitis, West Nile Fever and further undisclosed targets on the basis of the Themaxyn platform.